Cargando…
Expression of Concern to: Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248857/ https://www.ncbi.nlm.nih.gov/pubmed/35362056 http://dx.doi.org/10.1093/jnci/djac065 |
Ejemplares similares
-
Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
Publicado: (2019) -
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without
Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell
Lung Cancer
por: Wang, Xiao-Shan, et al.
Publicado: (2022) -
Correction to: Randomized trial of First-Line tyrosine kinase inhibitor with
or without radiotherapy for synchronous oligometastatic EGFR-Mutated
Non-Small cell lung cancer
Publicado: (2023) -
Expression of Concern. EGFR Tyrosine Kinase Inhibitor (PD153035) Improves
Glucose Tolerance and Insulin Action in High-Fat Diet–Fed Mice. Diabetes
2009;58:2910–2919. DOI: 10.2337/db08-0506. PMID: 19696185
por: Prada, Patricia O., et al.
Publicado: (2017) -
Expression of Concern: A Histopathological Feature of EGFR-Mutated Lung Adenocarcinomas with Highly Malignant Potential – An Implication of Micropapillary Element -
Publicado: (2023)